The HIT-TRAP Trial

Status Active, not recruiting

Clinical Trial Summary

Randomised, double blind trial in non-intensive care trauma patients comparing unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in heparin-induced thrombocytopenia (HIT).

Clinical Trial Description

This is a randomised, double blind trial including trauma patients with need for thrombosis prophylaxis with heparin. Patients receive either unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH).

Heparin-induced thrombocytopenia (HIT) antibodies are measured on days 1 and 10. There are daily platelet counts. On discharge an ultrasound doppler of the lower extremities is performed to rule out deep vein thrombosis (DVT).

Three months after discharge every patient is answering a questionnaire about thromboembolic complications following discharge.

The key questions of the study are whether the two heparins cause HIT-antibodies in differing frequencies, and if yes, whether these differences lead to different clinical outcomes. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00196417
Study type	Interventional
Source	University Medicine Greifswald
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	January 2003
Completion date	November 2005

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00759083` - Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients	Phase 4
Completed	`NCT00412464` - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis	Phase 1
Completed	`NCT00456326` - Heparin-Induced Thrombocytopenia Registry	N/A
Terminated	`NCT00673439` - Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)	Phase 2
Active, not recruiting	`NCT00198575` - A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients	N/A
Completed	`NCT00283322` - Heparin Antibodies in Intensive Care Unit Patients (HAICU)	N/A
Not yet recruiting	`NCT05586854` - Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia	N/A
Not yet recruiting	`NCT03269019` - Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia	N/A
Not yet recruiting	`NCT06066762` - Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
Terminated	`NCT03809481` - Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban	Phase 3
Completed	`NCT05325346` - A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects	Phase 1
Recruiting	`NCT02717039` - Pharmacogenomics of Heparin-Induced Thrombocytopenia
Completed	`NCT02526485` - Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
Completed	`NCT00748839` - Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical	N/A
Recruiting	`NCT05783895` - Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery
Not yet recruiting	`NCT04782843` - Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
Completed	`NCT00198588` - Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia	Phase 3
Recruiting	`NCT04842760` - PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
Terminated	`NCT01598168` - Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia	Phase 3
Completed	`NCT01654848` - Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients	N/A